Zara Pietro, Floris Valentina, Flanagan Eoin P, Lopez-Chiriboga A Sebastian, Weinshenker Brian G, Solla Paolo, Sechi Elia
Department of Medical, Surgical and Experimental Sciences, University of Sassari - AOU Sassari, Sassari, Italy.
Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Mult Scler J Exp Transl Clin. 2021 Nov 19;7(4):20552173211048761. doi: 10.1177/20552173211048761. eCollection 2021 Oct.
Myelin-oligodendrocyte-glycoprotein (MOG)-IgG-positivity in patients with typical MS lesions on MRI may lead to diagnostic/therapeutic uncertainty.
We reviewed reports of cases with MS phenotype on MRI and MOG-IgG-positivity published in Pubmed between 01/2012-06/2021.
Sixteen patients were included (median age [range], 37,5 [25-66] years; 60% female). Three patients initially tested negative for MOG-IgG. Disease course was: relapsing-remitting, 10; or progressive, 6. Intrathecal IgG-synthesis was common (79%). Low and high-efficacy MS-targeted agents prevented relapses in 30% and 100%, respectively. None of the patients showed resolution of MRI T2-lesions over time.
MOG-IgG-positivity is unlikely to alter the expected treatment response and outcomes in patients with otherwise typical MS phenotype on MRI.
MRI显示典型多发性硬化（MS）病灶的患者中，髓鞘少突胶质细胞糖蛋白（MOG）-IgG阳性可能导致诊断/治疗的不确定性。
我们回顾了2012年1月至2021年6月期间发表在Pubmed上的MRI表现为MS表型且MOG-IgG阳性的病例报告。
纳入16例患者（中位年龄[范围]，37.5[25-66]岁；60%为女性）。3例患者最初MOG-IgG检测为阴性。病程为：复发缓解型，10例；或进展型，6例。鞘内IgG合成常见（79%）。低效能和高效能的MS靶向药物分别使30%和100%的患者预防了复发。随着时间推移，没有患者的MRI T2病灶消退。
对于MRI表现为其他典型MS表型的患者，MOG-IgG阳性不太可能改变预期的治疗反应和结果。
